05:32 AM EDT, 09/15/2026 (MT Newswires) -- MaaT Pharma (MAAT.PA) said Tuesday the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative trend opinion following the oral explanation for its gastrointestinal acute graft-versus-host disease investigational therapy MaaT013, or Xervyteg. The panel issued the opinion following the explanation conducted as part of the re-examination procedure of its conditional marketing authorization application. The clinical-stage pharmaceutical company said the committee reaffirmed that the current clinical data package, particularly without a randomized controlled trial, does not establish the benefit or risk profile of Xervyteg. The therapy is used to treat acute graft-versus-host disease in adult patients with gastrointestinal involvement refractory to prior lines of therapy. CHMP's formal opinion is expected on Friday.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.